Want to see SE:ACARIX full AI Analyst Report?
Top Page
Acarix AB
(ACARIX)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr0.18
▼(-36.07% Downside)
Action:Reiterated
Date:10/02/26
The score is primarily held down by very large ongoing operating losses and persistent negative cash flow, implying continued external funding needs despite some improvement. Technicals are neutral-to-weak with price below key longer-term averages and a negative MACD. Valuation provides limited support because earnings are negative and no dividend yield is available.
Positive Factors
Revenue and gross-margin improvement
Rising revenue alongside a substantial gross-margin improvement indicates that Acarix is gaining commercial traction while achieving better economics on sales. If maintained, this combination can provide a stronger foundation for operating leverage and reduce the revenue scale needed to approach breakeven.
Negative Factors
Deep and persistent operating losses
Profitability remains far below breakeven despite revenue growth and improved gross margin, showing that the current cost structure is not yet supported by the business's revenue base. Continued deep losses could delay self-sufficiency and require substantial operating improvement before earnings become durable.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and gross-margin improvement
Rising revenue alongside a substantial gross-margin improvement indicates that Acarix is gaining commercial traction while achieving better economics on sales. If maintained, this combination can provide a stronger foundation for operating leverage and reduce the revenue scale needed to approach breakeven.
Read all positive factors
Acarix AB (ACARIX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr229.00M
Dividend YieldN/A
Average Volume (3M)1.46M
Price to Earnings (P/E)―
Beta (1Y)0.09
Revenue Growth65.82%
EPS Growth41.28%
CountrySE
Employees8
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.04
Shares Outstanding1,240,511,600
10 Day Avg. Volume1,117,210
30 Day Avg. Volume1,460,728
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)7.91
Price to Sales (P/S)41.02
P/FCF Ratio-6.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr19.10M
Acarix AB Business Overview & Revenue Model
Company Description
Acarix AB (publ) is a medical technology company that develops and introduces diagnostic solutions for cardiovascular conditions to markets including Germany, Sweden, the Middle East, Switzerland, Austria, and globally. Their key product is the CA...
Acarix AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.22M | 7.36M | 6.20M | 6.24M | 5.82M | 3.76M |
| Gross Profit | 5.15M | 2.76M | 5.59M | 5.30M | 4.62M | 2.82M |
| EBITDA | -34.79M | -44.53M | -62.63M | -74.62M | -73.78M | -48.28M |
| Net Income | -39.38M | -48.09M | -66.19M | -77.84M | -76.98M | -51.80M |
Balance Sheet | ||||||
| Total Assets | 47.74M | 48.33M | 80.76M | 62.88M | 69.48M | 118.60M |
| Cash, Cash Equivalents and Short-Term Investments | 28.88M | 18.27M | 53.99M | 35.15M | 11.31M | 15.81M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 251.00K | 523.00K |
| Total Liabilities | 3.96M | 10.16M | 5.06M | 11.00M | 17.66M | 18.06M |
| Stockholders Equity | 43.78M | 38.17M | 75.70M | 51.88M | 51.83M | 100.54M |
Cash Flow | ||||||
| Free Cash Flow | -23.23M | -49.14M | -64.25M | -81.37M | -75.02M | -48.05M |
| Operating Cash Flow | -34.77M | -48.38M | -63.33M | -81.37M | -74.87M | -48.01M |
| Investing Cash Flow | -454.00K | -757.00K | -920.00K | 0.00 | -151.00K | -43.00K |
| Financing Cash Flow | 32.04M | 11.11M | 86.98M | 106.23M | 69.03M | -164.00K |
Acarix AB Technical Analysis
Negative
0.28
Price Trends
0.21
Negative
0.23
Negative
0.25
Negative
Market Momentum
>-0.01
Positive
40.26
Neutral
15.72
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACARIX, the sentiment is Negative. The current price of 0.28 is above the 20-day moving average (MA) of 0.20, above the 50-day MA of 0.21, and above the 200-day MA of 0.25, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.26 is Neutral, neither overbought nor oversold. The STOCH value of 15.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACARIX.
Acarix AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr65.76B | 103.06 | 30.26% | 0.39% | 13.94% | 5.70% | |
58 Neutral | kr450.01M | -93.40 | -3.61% | ― | 15.87% | 92.43% | |
53 Neutral | kr541.43M | 85.83 | 1.93% | ― | -0.51% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | kr138.09M | -2.30 | -54.68% | ― | ― | ― | |
44 Neutral | kr444.13M | -3.98 | -37.43% | ― | 27.40% | 26.07% | |
42 Neutral | kr229.00M | -5.43 | -100.09% | ― | 65.82% | 41.28% |
* Healthcare Sector Average
SE:ACARIX
Acarix AB
0.18
-0.10
-34.52%
SE:SEZI
Senzime AB
2.83
-3.08
-52.12%
SE:BACTI.B
Bactiguard Holding AB
15.45
-0.85
-5.21%
SE:SECT.B
Sectra AB Class B
337.00
31.83
10.43%
SE:HEART
Scandinavian Real Heart AB
16.25
-0.59
-3.50%
SE:MNTC
Mentice AB
16.00
5.90
58.42%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.